< 1 minute read
Feb. 9, 2022

Giredestrant (GDC-9545): an Oral Selective Estrogen Receptor Degrader and Full Antagonist

Genentech ER Degrader

selective ER degrader (SERD) + full antag. oral (30 mg QD), Ph. III for ER+, HER2- BC from profiling >4k cmpds for desired MoA giredestrant (GDC-9545) Genentech, South San Francisco, CA


Molecules of the Month

MOTY Nominees

Molecule of the Year